Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. [electronic resource]
Producer: 20120224Description: 5783-92 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Alleles
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Capecitabine
- Chemokines -- genetics
- Colorectal Neoplasms -- blood supply
- Cytokines -- genetics
- Deoxycytidine -- analogs & derivatives
- Disease-Free Survival
- Female
- Fluorouracil -- analogs & derivatives
- Genetic Variation
- Genotype
- Humans
- Leucovorin -- therapeutic use
- Male
- Middle Aged
- Neovascularization, Pathologic -- drug therapy
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Oxaloacetates
- Pharmacogenetics
- Polymorphism, Restriction Fragment Length
- Polymorphism, Single Nucleotide
- Vascular Endothelial Growth Factor A -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.